Caterina Montani, Carola Canella, Adam J Schwarz, Jennifer Li, Gary Gilmour, Alberto Galbusera, Keith Wafford, Daniel Gutierrez-Barragan, Andrew McCarthy, David Shaw, Karen Knitowski, David McKinzie, Alessandro Gozzi, Christian Felder
Cholinergic drugs acting at M1/M4 muscarinic receptors hold promise for the treatment of symptoms associated with brain disorders characterized by cognitive impairment, mood disturbances, or psychosis, such as Alzheimer's disease or schizophrenia. However, the brain-wide functional substrates engaged by muscarinic agonists remain poorly understood. Here we used a combination of pharmacological fMRI (phMRI), resting-state fMRI (rsfMRI), and resting-state quantitative EEG (qEEG) to investigate the effects of a behaviorally active dose of the M1/M4-preferring muscarinic agonist xanomeline on brain functional activity in the rodent brain...
December 20, 2020: Neuropsychopharmacology